BE Study of Gaster®D Tab 20mg (Manufacturer Changed)
Status:
Unknown status
Trial end date:
2020-01-03
Target enrollment:
Participant gender:
Summary
An Open-Label, Randomized, Two-sequence, Two-period, Fasting Condition, Single Oral Dose,
Cross-over Study of Bioequivalence of "Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
and "Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)" in
Healthy, Adult, Human Subjects.